In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

A price cut for semaglutide in Medicare could also have spillover effects, pressuring prices for Eli Lilly’s Mounjaro ...

On that note, time to hustle. Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

Teva launched an authorized generic for Victoza ... Meanwhile, Novo’s chief rival in the metabolic medicine space, Eli Lilly, adopted a similar tack this week when it filed a motion to intervene ...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available ... That puts Emgality ahead of Teva’s Ajovy (fremanezumab), which picked up a positive opinion ...

In its petition, Novo Nordisk (NVO) noted that Teva (NYSE:TEVA ... Earlier this week, rival Eli Lilly (LLY) filed a motion with a federal court to join in on a case filed by the OFA over the ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

“The point is that, according to the researchers’ argument, deprivation lies on a path of cause and effect going from having ADHD to having a lower life expectancy, and adjusting for deprivation could ...